Muntasir Mamun Majumder
Overview
Explore the profile of Muntasir Mamun Majumder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fogal V, Michopoulos F, Jarnuczak A, Hamza G, Harlfinger S, Davey P, et al.
Arch Toxicol
. 2024 May;
98(8):2589-2603.
PMID: 38755480
The tumour suppressor p16/CDKN2A and the metabolic gene, methyl-thio-adenosine phosphorylase (MTAP), are frequently co-deleted in some of the most aggressive and currently untreatable cancers. Cells with MTAP deletion are vulnerable...
2.
Tran Minh M, Tamminen M, Tamminen-Sirkia J, Majumder M, Tabassum R, Lahti T
BMJ Open
. 2022 May;
12(5):e053693.
PMID: 35534065
Objectives: This study explored self-reported knowledge and interest to learn more about medicines research, development and health technology assessment among Finnish general public. It also aimed to define possible knowledge...
3.
Liu M, Wang Y, Miettinen J, Kumari R, Majumder M, Tierney C, et al.
Front Cell Dev Biol
. 2021 Sep;
9:723016.
PMID: 34485305
Despite several new therapeutic options, multiple myeloma (MM) patients experience multiple relapses and inevitably become refractory to treatment. Insights into drug resistance mechanisms may lead to the development of novel...
4.
Kumari R, Majumder M, Lievonen J, Silvennoinen R, Anttila P, Nupponen N, et al.
Br J Cancer
. 2021 Feb;
124(8):1428-1436.
PMID: 33531688
Background: Esterase enzymes differ in substrate specificity and biological function and may display dysregulated expression in cancer. This study evaluated the biological significance of esterase expression in multiple myeloma (MM)....
5.
Malyutina A, Majumder M, Wang W, Pessia A, Heckman C, Tang J
PLoS Comput Biol
. 2019 May;
15(5):e1006752.
PMID: 31107860
High-throughput drug screening has facilitated the discovery of drug combinations in cancer. Many existing studies adopted a full matrix design, aiming for the characterization of drug pair effects for cancer...
6.
Sundin I, Peltola T, Micallef L, Afrabandpey H, Soare M, Majumder M, et al.
Bioinformatics
. 2018 Jun;
34(13):i395-i403.
PMID: 29949984
Motivation: Precision medicine requires the ability to predict the efficacies of different treatments for a given individual using high-dimensional genomic measurements. However, identifying predictive features remains a challenge when the...
7.
Alzrigat M, Parraga A, Majumder M, Ma A, Jin J, Osterborg A, et al.
Oncotarget
. 2017 Dec;
8(61):103731-103743.
PMID: 29262596
Multiple myeloma (MM) is a tumor of plasmablasts/plasma cells (PCs) characterized by the expansion of malignant PCs with complex genetic aberrations in the bone marrow (BM). Recent reports, by us...
8.
Majumder M, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, et al.
Oncotarget
. 2017 Sep;
8(34):56338-56350.
PMID: 28915594
Novel agents have increased survival of multiple myeloma (MM) patients, however high-risk and relapsed/refractory patients remain challenging to treat and their outcome is poor. To identify novel therapies and aid...
9.
Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al.
Sci Rep
. 2014 Jun;
4:5193.
PMID: 24898935
We developed a systematic algorithmic solution for quantitative drug sensitivity scoring (DSS), based on continuous modeling and integration of multiple dose-response relationships in high-throughput compound testing studies. Mathematical model estimation...
10.
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al.
Cancer Discov
. 2013 Sep;
3(12):1416-29.
PMID: 24056683
Unlabelled: We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profiling and ex vivo drug...